Dr. Subramaniam discusses using new high-tech microscopes in cancer research

Posted: Jul 21, 2016

Dr. Subramaniam discusses the new multimillion-dollar cryo-electron microscope installed this year at the Advanced Technology Research Facility (ATRF) in Frederick with the Frederick News Post.
Dr. Subramaniam discusses using new high-tech microscopes in cancer research

CURE Magazine Honors CCR Nurse Cindy Delbrook As “An Extraordinary Healer”

Posted: Jul 14, 2016

The Pediatric Oncology Branch’s (POB) Cindy Delbrook was recently honored by CURE Magazine as “An Extraordinary Healer” nominee. Written by former Investigator, Daniel “Trey” Lee, the essay is speaks to Cindy’s incredible dedication and compassion as an advocate, caregiver and friend to countless children and families that have passed through her door.
CURE Magazine Honors CCR Nurse Cindy Delbrook As “An Extraordinary Healer”

Dr. Jung-Min Lee Appointed as Lasker Scholar Investigator

Posted: Jul 12, 2016

CCR is pleased to announce the appointment of Jung-Min Lee, M.D. as a Lasker Scholar Investigator in the Women’s Malignancies Branch. Dr. Lee’s research focuses on investigating the biology of breast and ovarian cancers, developing novel therapeutic strategies, and evaluating these therapeutic approaches in clinical trials.
Dr. Jung-Min Lee Appointed as Lasker Scholar Investigator

Clinical Trial Combines Enzalutamide With Immunotherapy for Advanced Prostate Cancer

Posted: Jul 11, 2016

Dr. Ravi Madan, Clinical Director of the Genitourinary Malignancies Branch, is conducting a clinical trial for men who have metastatic prostate cancer but have not yet been treated with chemotherapy, abiraterone or enzalutamide.
Clinical Trial Combines Enzalutamide With Immunotherapy for Advanced Prostate Cancer

New Clinical Trial Combines LMB-100 with Nab-Paclitaxel for Metastatic or Locally Advanced Pancreatic Cancer

Posted: Jul 8, 2016

Christine Alewine, Lasker Scholar, in the Laboratory of Molecular Biology is conducting a clinical study for patients with pancreatic cancer using a new immunotoxin drug, called LMB-100. It is a targeted immunotherapy that delivers a toxin to cancer cells that make a protein called mesothelin that is made by most pancreatic cancers.
New Clinical Trial Combines LMB-100 with Nab-Paclitaxel for Metastatic or Locally Advanced Pancreatic Cancer

CCR Researchers Find DNA-binding Triggers Tetramerization of Glucocorticoid Receptor in Live Cells

Posted: Jul 7, 2016

The glucocorticoid receptor (GR) is a ligand-regulated transcription factor and one of the most targeted proteins in the pharmaceutical industry due to its powerful antiinflammatory actions. The search for side effects-free glucocorticoids relies exclusively on a model wherein the GR oligomerization state, whether a monomer or a dimer, dictates its transcriptional output. Here, Dr. Gordon Hager, Dr. Diego Presman, and colleagues use an experimental approach where the GR–DNA interaction is observed in real time with a technique that allows the quantification of the oligomeric state of proteins in living cells. Unexpectedly, they find that DNA binding triggers tetramerization of the GR, which would be the truly activated form of the receptor. Their findings reveal a previously unidentified step in the glucocorticoid activation pathway.
CCR Researchers Find DNA-binding Triggers Tetramerization of Glucocorticoid Receptor in Live Cells

CCR Investigators Among World Leaders in Sarcoma Research

Posted: Jul 1, 2016

To recognize Sarcoma Awareness Month this July, we are highlighting our researchers who are advancing research discovery in this field.
CCR Investigators Among World Leaders in Sarcoma Research

CCR Investigators Use Liquid Biopsies to Uncover Cancer in the Blood of Lymphoma Patients

Posted: Jun 28, 2016

CCR investigators are using circulating tumor DNA (ctDNA) as a type of noninvasive liquid biopsy for patients with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma. are using circulating tumor DNA (ctDNA) as a type of noninvasive liquid biopsy for patients with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma.
CCR Investigators Use Liquid Biopsies to Uncover Cancer in the Blood of Lymphoma Patients

CCR Connections | Volume 10 - No 1

Posted: Jun 27, 2016

The latest issue of CCR connections is out now, check it out!
CCR Connections | Volume 10 - No 1

New Developments in Active Surveillance for Prostate Cancer

Posted: Jun 27, 2016

Drs. Peter Choyke (Molecular Imaging Program, CCR) and Stacy Loeb (New York University Langone Medical Center) talk to CancerNetwork about the progress that has been made in active surveillance for prostate cancer.
New Developments in Active Surveillance for Prostate Cancer

Pages